Compare CCC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCC | BLTE |
|---|---|---|
| Founded | 1980 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.1B |
| IPO Year | N/A | 2022 |
| Metric | CCC | BLTE |
|---|---|---|
| Price | $5.57 | $182.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $10.38 | ★ $161.57 |
| AVG Volume (30 Days) | ★ 13.2M | 241.4K |
| Earning Date | 02-24-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,025,600,000.00 | N/A |
| Revenue This Year | $12.72 | N/A |
| Revenue Next Year | $9.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.64 | N/A |
| 52 Week Low | $5.57 | $49.00 |
| 52 Week High | $11.23 | $200.00 |
| Indicator | CCC | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 18.15 | 63.06 |
| Support Level | $5.57 | $175.18 |
| Resistance Level | $7.64 | $192.94 |
| Average True Range (ATR) | 0.36 | 11.25 |
| MACD | -0.26 | 1.50 |
| Stochastic Oscillator | 7.40 | 59.96 |
CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, and AI-enabled digital workflows. It operates in a single segment being Domestic segment which provides SAAS platform for the P&C insurance economy and derives revenues from providing customers with software subscriptions to the platform in addition to providing professional services and non-software services. The company has its presence in United States and China. Majority of the revenue is generated from United States.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.